A Study to Assess the Safety, Feasibility, and Immunogenicity of Personalized Neoantigen-based Dendritic Cell Vaccine in Combination With Microwave Ablation to Treat Hepatocellular Carcinoma
Latest Information Update: 09 Jul 2024
At a glance
- Drugs LK-101 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
Most Recent Events
- 04 Jun 2024 Results evaluating the safety and T cell immune response of a personalized neoantigen-based mRNA loaded dendritic cell (DC) vaccine (LK101) combined with regular ablation in patients with HCC presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 23 Mar 2023 According to a ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified-October 2018).
- 23 Mar 2023 New trial record